Sufentanil Sublingual for Acute Post-Operative Pain: A Systematic Literature Review Focused on Pain Intensity, Adverse Events, and Patient Satisfaction.
Adverse events (AEs)
Pain intensity
Patient satisfaction
Patient-controlled analgesia (PCA)
Post-operative pain
Sufentanil sublingual tablet system (SSTS)
Journal
Pain and therapy
ISSN: 2193-8237
Titre abrégé: Pain Ther
Pays: New Zealand
ID NLM: 101634491
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
10
03
2020
pubmed:
19
4
2020
medline:
19
4
2020
entrez:
19
4
2020
Statut:
ppublish
Résumé
Pain is commonly experienced among patients after surgical procedures. Clinical pain management after surgery is far from being successful. Patients may control postoperative pain by self-administration of intravenous opioids using devices designed for this purpose (patient-controlled analgesia or PCA). PCA devices have been developed including the sufentanil sublingual tablet system (SSTS). A systematic review of the use of SSTS for postoperative pain is needed to identify an alternative method of pain management. To systematically review literature to establish the efficacy and the safety of PCA with SSTS used in the treatment of moderate-to-severe acute post-operative pain in a hospital setting. Embase, MEDLINE, Google Scholar, and Cochrane Central Trials Register were systematically searched in December 2019 for studies examining SSTS for pain in adult after surgical procedures. The methodological quality of the studies and their results were appraised using the Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN) checklist and specific measurement properties criteria, respectively. Sixteen studies evaluating SSTS were included for a total of 2311 patients. All participants in the SSTS group reported NRS ≤ 4 within 24 h after surgery. Patient satisfaction was high, with a minimum of 70% satisfaction among patients treated with SSTS. The most common adverse events (AEs) overall for SSTS 15 and 30 mcg were nausea, vomiting, and headache. AEs observed in the studies were generally consistent with those associated with opioids and the postsurgical setting. SSTS is an important system for the management of moderate-to-severe acute pain in a hospital setting. SSTS is well tolerated, with no unexpected adverse events (AEs) and no clinically meaningful vital sign changes. These data confirm the safety and tolerability of the SSTS. Successful pain management resulted in a high level of acceptance of the SSTS by patients with high satisfaction for the method of pain control.
Identifiants
pubmed: 32303979
doi: 10.1007/s40122-020-00166-4
pii: 10.1007/s40122-020-00166-4
pmc: PMC7203368
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
217-230Références
Weiser TG, Regenbogen SE, Thompson KD, et al. An estimation of the global volume of surgery: a modelling strategy based on available data. Lancet. 2008;372:139–44.
doi: 10.1016/S0140-6736(08)60878-8
Zaslansky R, Rothaug J, Chapman CR, et al. PAIN OUT: the making of an international acute pain registry. Eur J Pain. 2015;19:490–502.
doi: 10.1002/ejp.571
Baratta JL, Schwenk ES, Viscusi ER. Clinical consequences of inadequate pain relief: barriers to optimal pain management. Plast Reconstr Surg. 2014;134(4Suppl2):15S–21S.
doi: 10.1097/PRS.0000000000000681
Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg. 2003;97:534–40.
doi: 10.1213/01.ANE.0000068822.10113.9E
Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of Postoperative Pain: a Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists’ Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016;17(2):131–57.
doi: 10.1016/j.jpain.2015.12.008
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
doi: 10.1136/bmj.b2535
Terwee CB, Mokkink LB, Knol DL. Rating the methodological quality in systematic reviews of studies on measurement properties: a scoring system for the COSMIN checklist. Qual Life Res. 2012;21(4):651–7.
doi: 10.1007/s11136-011-9960-1
Mokkink LB, Terwee CB, Patrick DL. The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study. Qual Life Res. 2010;19(4):539–49.
doi: 10.1007/s11136-010-9606-8
Costa F, Pascarella G, Piliego C, et al. Sufentanil sublingual tablet system (Zalviso
doi: 10.4103/sja.SJA_109_19
Dransart C, De Bue P, Jamart J, et al. Sublingual sufentanil tablet system for postoperative pain relief after spinal lumbar neurosurgery. A retrospective comparison with IV morphine patient-controlled analgesia. J Clin Anesth Pain Med. 2018;2(2):22.
Hutchins JL, Leiman D, Minkowitz HS, et al. An open-label study of sufentanil sublingual tablet 30 mcg in patients with postoperative pain. Pain Med. 2018;19:2058–68.
doi: 10.1093/pm/pnx248
Jove M, Griffin DW, Minkowitz HS, et al. Sufentanil sublingual tablet system for the management of postoperative pain after knee or hip arthroplasty: a randomized placebo-controlled study. Anesthesiology. 2015;123(2):434–43.
doi: 10.1097/ALN.0000000000000746
Lakshman S, Minkowitz H, Melson T, Leiman D. Abstract: safety and efficacy of sufentanil sublingual 30 mcg tablets for the treatment of acute pain following outpatient abdominoplasty. Plast Reconstr Surg Glob Open. 2016;4(9 Suppl):58–9.
doi: 10.1097/01.GOX.0000502942.62522.e4
Leykin Y, Laudani A, Busetto N, et al. Sublingual sufentanil tablet system for postoperative analgesia after gynecological surgery. Minerva Med. 2019;110:209–15.
doi: 10.23736/S0026-4806.19.05992-5
Meijer F, Cornelissen P, Sie C, et al. Sublingual sufentanil for postoperative pain relief: first clinical experiences. J Pain Res. 2018;11:987–92.
doi: 10.2147/JPR.S160091
Melson TI, Boyer DL, Minkowitz HS, et al. Sufentanil sublingual tablet system vs intravenous patient-controlled analgesia with morphine for postoperative pain control: a randomized, active-comparator trial. Pain Pract. 2014;14(8):679–88.
doi: 10.1111/papr.12238
Miner JR, Rafique Z, Minkowitz HS, DiDonato KP, Palmer PP. Sufentanil sublingual tablet 30 mcg for moderate-to-severe acute pain in the ED. Am J Emerg Med. 2018;36(6):954–61.
doi: 10.1016/j.ajem.2017.10.058
Minkowitz HS, Leiman D, Melson T, et al. Sufentanil sublingual tablet 30 mcg for the management of pain following abdominal surgery: a randomized, placebo-controlled, phase-3 study. Pain Pract. 2017;17:848–58.
doi: 10.1111/papr.12531
Pogatzki-Zahn E, Kranke P, Winner J, et al. Real-world use of the sufentanil sublingual tablet system for patient-controlled management of acute postoperative pain: a prospective noninterventional study. Curr Med Res Opin. 2019;30:1–8.
Ringold FG, Minkowitz HS, Gan TJ, et al. Sufentanil sublingual tablet system for the management of postoperative pain following open abdominal surgery: a randomized. Placebo-Controlled Study. Reg Anesth Pain Med. 2015;40:22–30.
doi: 10.1097/AAP.0000000000000152
Rispoli M, Fiorelli A, Nespoli MR, et al. Sufentanil sublingual tablet system for the management of postoperative pain after video-assisted thoracic surgery: a preliminary clinical experience. J Cardiothorac Vasc Anesth. 2018;32(3):e61–3.
doi: 10.1053/j.jvca.2017.11.015
Scardino M, D’Amato T, Martorelli F, et al. Sublingual sufentanil tablet system Zalviso
doi: 10.1186/s40634-018-0123-y
Turi S, Deni F, Lombardi G, et al. Sufentanil sublingual tablet system (SSTS) for the management of postoperative pain after major abdominal and gynecological surgery within an ERAS protocol: an observational study. J Pain Res. 2019;12:2313–9.
doi: 10.2147/JPR.S214600
van Veen DE, Verhelst CCWM, van Dellen RT, Koopman J. Sublingual sufentanil (Zalviso) patient-controlled analgesia after total knee arthroplasty: a retrospective comparison with oxycodone with or without dexamethasone. J Pain Res. 2018;14(11):3205–10.
doi: 10.2147/JPR.S185197
Mather LE. Opioids—a pharmacologist’s delight! Clin Exp Pharmacol Physiol. 1995;22(11):833–6.
doi: 10.1111/j.1440-1681.1995.tb01945.x
van de Donk T, Ward S, Langford R, Dahan A. Pharmacokinetics and pharmacodynamics of sublingual sufentanil for postoperative pain management. Anaesthesia. 2018;73:231–7.
doi: 10.1111/anae.14132
Gerbershagen HJ, Rothaug J, Kalkman CJ, Meissner W. Determination of moderate-to-severe postoperative pain on the numeric rating scale: a cut-off point analysis applying four different methods. Br J Anaesth. 2011;107(4):619–26.
doi: 10.1093/bja/aer195
Cepeda MS, Africano JM, Polo R, Alcala R, Carr DB. What decline in pain intensity is meaningful to patients with acute pain? Pain. 2003;105:151–7.
doi: 10.1016/S0304-3959(03)00176-3